Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders

NCT03601819 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

4

Enrollment

OTHER

Sponsor class

Stopped Low accrual

Conditions

Lymphoma, T-Cell, Cutaneous
Lymphoma, T-Cell, Peripheral
Chronic Lymphocytic Leukemia
Lymphoproliferative Disorders
Waldenstrom Macroglobulinemia
Lymphoplasmacytic Lymphoma
Mantle Cell Lymphoma

Interventions

DRUG: Pacritinib

Sponsor

University of Michigan Rogel Cancer Center